Scott Braunstein, Marinus Pharmaceuticals CEO
June 17, 2024 10:37 AM EDT
R&D

Mar­i­nus re­ports mixed Phase 3 re­sults on IV seizure drug

Lei Lei Wu

News Reporter

Mar­i­nus Phar­ma­ceu­ti­cals re­port­ed Mon­day that its IV drug met on­ly one of two key end­points in a Phase 3 study for pro­longed seizures.

In the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bio­gen gets $250M in Roy­al­ty Phar­ma deal for Phase 3 lu­pus pro­gram

Ab­b­Vie pens an­oth­er T cell en­gager deal, this time with Xilio

Af­ter pass­ing on M&A of­fers, Abcuro rais­es $200M in bid to be­come com­mer­cial drug­mak­er

Ex­clu­sive: Longevi­ty start­up tar­gets rene­gade pro­teins linked to di­a­betes and obe­si­ty

Spring­Works lands FDA ap­proval for nerve tu­mor treat­ment

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times